Jump Financial LLC Invests $469,000 in Immatics (NASDAQ:IMTX)

Jump Financial LLC purchased a new stake in shares of Immatics (NASDAQ:IMTXFree Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 40,470 shares of the company’s stock, valued at approximately $469,000. Jump Financial LLC owned approximately 0.05% of Immatics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. TD Asset Management Inc raised its stake in shares of Immatics by 102.8% during the third quarter. TD Asset Management Inc now owns 197,718 shares of the company’s stock valued at $2,290,000 after purchasing an additional 100,200 shares during the period. Affinity Asset Advisors LLC acquired a new position in Immatics in the second quarter worth $3,462,000. Woodline Partners LP boosted its holdings in Immatics by 24.1% in the second quarter. Woodline Partners LP now owns 1,213,884 shares of the company’s stock worth $14,008,000 after purchasing an additional 235,922 shares during the period. Hudson Bay Capital Management LP boosted its holdings in Immatics by 72.4% in the second quarter. Hudson Bay Capital Management LP now owns 370,580 shares of the company’s stock worth $4,276,000 after purchasing an additional 155,580 shares during the period. Finally, 683 Capital Management LLC boosted its holdings in Immatics by 1.1% in the second quarter. 683 Capital Management LLC now owns 1,350,000 shares of the company’s stock worth $15,579,000 after purchasing an additional 15,063 shares during the period. 53.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald started coverage on shares of Immatics in a report on Thursday, November 2nd. They issued an “overweight” rating for the company.

View Our Latest Stock Report on Immatics

Immatics Stock Up 0.8 %

Shares of IMTX opened at $11.39 on Friday. The firm has a market capitalization of $964.28 million, a PE ratio of -9.41 and a beta of 0.68. The firm has a 50-day moving average price of $10.76 and a 200 day moving average price of $10.62. Immatics has a 52-week low of $5.90 and a 52-week high of $13.14.

Immatics (NASDAQ:IMTXGet Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.07. Immatics had a negative net margin of 113.43% and a negative return on equity of 38.27%. The business had revenue of $6.45 million during the quarter, compared to analysts’ expectations of $11.05 million. On average, equities analysts expect that Immatics will post -1.32 EPS for the current year.

Immatics Company Profile

(Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Featured Stories

Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics (NASDAQ:IMTXFree Report).

Institutional Ownership by Quarter for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.